RNA BIOCHEMISTRY IS ONE OF THE MOST PROMISING AREAS OF MEDICINAL INNOVATION

First Health Pharmaceuticals has a leading position in the field of advanced RNA biochemistry. We aim to further develop our portfolio of highly active patented RNA Helicase inhibiting lead compounds and bring revolutionary pharmaceuticals to the market that will offer new hope for patients suffering from some of the most challenging diseases of our time.

HIV

First Health Pharmaceuticals developed the first ever generation of Translation Inhibitor antiretroviral compounds effective against HAART resistant HIV strains

BREAST CANCER

The role of DDX3 in breast cancer has been studied most extensively. Our DDX3 Inhibitors were successfully tested on metastatic breast cancer cell lines expressing DDX3

DENGUE

No antivirus was thus far available against Dengue virus, but our anti Dengue lead compound demonstrates excellent antiviral activity combined with very low cytotoxicity

CYTOKINE STORM

DDX3 inhibition has a mitigating effect on the immune response which is one of the key triggering factors causing Cytokine Storm, suggesting a potential benefit in the treatment of haemorrhagic fever

LOW ATTRITION RATE

First Health Pharma prioritizes the development of compounds with optimal physico-chemical profile, from the early phases of drug discovery pipeline, to increase the chances of research project success.

 

COMPUTER-AIDED DRUG DESIGN

Through the use of proprietary software, statistical analysis tools and machine learning algorithms, First Health Pharmaceuticals brought computer aided drug development to a new level